Zegenex is developing topical treatments to help persistent wounds heal. Built on University of Pittsburgh research and licensed technology, its small-molecule platform is designed to reactivate the body's tissue-repair processes. The company's lead program focuses on diabetic foot ulcers, with potential applications in other chronic and complex wounds. [1]
Co-founded by Michael Tsang and Manush Saydmohammed, Zegenex brings regenerative biology into practical wound-care development. Its investigational formulations are designed for room-temperature storage and straightforward topical application, with the goal of making advanced wound care easier to deliver. The company is advancing its preclinical program toward human studies. [2] [1]